SuperworthCitroTech CITR
- Market cap
- $59.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 44.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1.3M
- −26% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −13.1%
CitroTech trades at 44.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $1.3M over the last twelve months, down 26% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $174.7K+818% | $262K+11643% | $433K+679% | $198.7K+601% | $107K−39% | $69.6K−73% | $969.4K+124% | $687.6K+246% | $288.2K+169% | $436.2K+526% | $344.9K−64% | $280.7K−59% | |
| Cost of revenue | $23.4K+1200% | $132.2K+139052% | $96.9K+144% | $102.2K+258% | $139.2K+496% | $454.8K+244% | $557K+475% | $371.4K+263% | $575.6K+314% | n/a | n/a | n/a |
| Gross profit | $151.3K+778% | $129.8K+5976% | $336.1K+2025% | $96.5K | −$32.1K | −$385.1K | $412.4K+23% | $316.2K+228% | −$287.4K+794% | n/a | n/a | n/a |
| R&D | n/a | n/a | n/a | n/a | n/a | n/a | $8K | $41.3K | n/a | n/a | $81.5K+915% | $197.1K+377% |
| SG&A | $106.2K−48% | $107.2K+13% | $187.7K+117% | $379K+261% | $272.8K+157% | $664.4K+520% | $307.7K+64% | $422.8K+12% | $582K+113% | $905.5K+36% | $547.6K+78% | $429.1K+2% |
| −$9.1M+2958% | −$182.3K−30% | −$2.6M+535% | −$907.4K+118% | −$561.4K−94% | −$1.2M+558% | −$3.5M+31% | −$3M+233% | −$4.2M+655% | −$5.8M+382% | −$4.4M+29% | −$3.5M+16% | |
| Interest expense | $1.8K+2216% | $1.8K+911% | $885+406% | $0 | $93.9K+5234% | $163K+8912% | $410.8K+46317% | $552.1K | $360.2K+284% | $187.8K+15% | $164.8K−60% | $3.6K−99% |
| Pre-tax income | −$9.1M+2958% | −$184.2K−29% | −$3.5M+747% | −$907.4K+117% | −$655.2K−93% | −$1.8M+877% | −$10.9M+210% | −$11.9M+1212% | −$7.9M+1110% | −$6.1M+239% | −$6.2M−43% | −$3.9M−67% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | −$9.1M+2958% | −$184.2K−29% | −$3.5M+747% | −$907.4K+117% | −$655.2K−93% | −$1.8M+877% | −$10.9M+210% | −$11.9M+1212% | −$7.9M+1110% | −$6.1M+239% | −$6.2M−43% | −$3.9M−67% |
| −$0.54 | $0.00 | −$0.24 | −$0.12 | −$0.11−80% | −$0.30 | −$1.37+471% | −$1.14+850% | −$0.59+436% | −$0.34+13% | −$0.33−76% | −$0.18−84% | |
| 16.3M+4% | 16.3M+4% | 15.4M−19% | 6.1M−68% | 6.1M−63% | 6.1M−63% | 8M−48% | 10.5M+72% | 13.5M+122% | 17.7M+192% | 18.8M+136% | 21.8M+108% |
Gross profit: 11 periods, Q1 FY23 to Q3 FY25: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY20 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest CitroTech's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CITRCitroTech | $59.8M | n/m | n/a | 44.3× | −26% | n/m | |
| FTLFFitlife Brands | $78.4M | 13.5× | 15.3× | 0.8× | +61% | 6.2% | |
| BTMDbiote | $38.4M | 10.7× | 12.3× | 0.2× | −8% | 3.2% | |
| NAGENiagen Bioscience | $192.3M | 13.5× | 27.0× | 1.5× | +11% | 12.4% | |
| Peer median | $78.4M | 13.5× | 15.3× | 0.8× | +11% | 6.2% |
More on CitroTech
Each number over time
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .